MX2007005199A - Indolizinas sustituidas y derivados como agentes del sistema nervioso central. - Google Patents

Indolizinas sustituidas y derivados como agentes del sistema nervioso central.

Info

Publication number
MX2007005199A
MX2007005199A MX2007005199A MX2007005199A MX2007005199A MX 2007005199 A MX2007005199 A MX 2007005199A MX 2007005199 A MX2007005199 A MX 2007005199A MX 2007005199 A MX2007005199 A MX 2007005199A MX 2007005199 A MX2007005199 A MX 2007005199A
Authority
MX
Mexico
Prior art keywords
derivatives
cns agents
compounds
indolizines
substituted
Prior art date
Application number
MX2007005199A
Other languages
English (en)
Inventor
Robert Lewis Vogel
Annmarie Louise Sabb
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2007005199A publication Critical patent/MX2007005199A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Se proporcionan compuestos de la formula (I) de sales farmaceuticamente aceptables de los mismos: formula (I)., los cuales son agonistas o agonistas parciales del subtipo 2C de receptores de serotonina cerebral. Los compuestos, y composiciones que contienen los compuestos, pueden utilizarse para tratar una variedad de trastornos del sistema nervioso central, tal como esquizofrenia.
MX2007005199A 2004-11-01 2005-10-27 Indolizinas sustituidas y derivados como agentes del sistema nervioso central. MX2007005199A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62442304P 2004-11-01 2004-11-01
PCT/US2005/038702 WO2006050007A2 (en) 2004-11-01 2005-10-27 Substituted indolizines and derivatives as cns agents

Publications (1)

Publication Number Publication Date
MX2007005199A true MX2007005199A (es) 2007-05-11

Family

ID=36177318

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007005199A MX2007005199A (es) 2004-11-01 2005-10-27 Indolizinas sustituidas y derivados como agentes del sistema nervioso central.

Country Status (9)

Country Link
US (1) US7608626B2 (es)
EP (1) EP1807427A2 (es)
JP (1) JP2008518917A (es)
CN (1) CN101094852A (es)
AU (1) AU2005302559A1 (es)
BR (1) BRPI0517955A (es)
CA (1) CA2585967A1 (es)
MX (1) MX2007005199A (es)
WO (1) WO2006050007A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2018863B9 (en) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
WO2009063992A1 (ja) 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited 縮合ピリジン誘導体およびその用途
WO2011031086A2 (ko) * 2009-09-10 2011-03-17 주식회사 엘지화학 신규한 헤테로고리 유도체 및 이를 이용한 유기 발광 소자
FR2953716B1 (fr) * 2009-12-16 2015-03-27 Oreal Kit de formulation d'un produit cosmetique
FR2961095B1 (fr) * 2010-06-09 2012-06-15 Oreal Composition cosmetique et/ou dermatologique comprenant au moins un compose 6-alcoxy tryptamine
FR2961097B1 (fr) * 2010-06-09 2012-07-13 Oreal Procede cosmetique de traitement des odeurs corporelles humaines utilisant un compose 6-alkoxy tryptamine
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
CN102295644B (zh) * 2011-05-25 2012-12-05 同济大学 一种合成1-卤-2-芳基中氮茚类化合物的方法
CN102603735B (zh) * 2012-02-06 2014-07-16 浙江新和成股份有限公司 一种c-2芳基化吲哚嗪化合物的制备方法
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
CN112010777B (zh) * 2020-08-20 2022-10-11 浙江大学衢州研究院 于管道化反应器内进行的酰胺连续化制备腈的方法
CA3236339A1 (en) * 2021-11-03 2023-05-11 Matthew BAGGOTT Indolizine compounds for the treatment of mental disorders or mental enhancement

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8416724D0 (en) 1984-06-30 1984-08-01 Sorbio Sa Lab Active compounds
EP0213696B1 (en) 1985-06-28 1991-01-23 Beecham Wuelfing GmbH & Co KG Tetrahydropyrido [1,2-a] indole derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
EP0252643A1 (en) 1986-07-01 1988-01-13 BEECHAM - WUELFING GmbH & Co. KG Pyrido[1,2-a]indole derivatives, process for their preparation and pharmaceutical compounds containing them
CA1329597C (en) 1986-12-22 1994-05-17 Dagmar Hoeltje Derivatives of tetrahydropyrido[1,2-a]indole
PT100570A (pt) 1991-06-07 1993-08-31 Smithkline Beecham Corp Compostos de pirrolo(1,2-a)indolo-hidroxiureia/hidroxamato, seu uso e preparacao e composicoes farmaceuticas que os contem
GB9316195D0 (en) 1993-08-05 1993-09-22 Smithkline Beecham Plc Pharmaceuticals
GB9318790D0 (en) 1993-09-10 1993-10-27 Fujisawa Pharmaceutical Co Heterocyclic derivatives
US6013653A (en) 1995-09-22 2000-01-11 Fujisawa Pharmaceuticals Co., Ltd. Processes for producing pyridoindole derivatives
IL129484A0 (en) 1998-04-17 2000-02-29 Lilly Co Eli Substituted tricyclics
AU4929999A (en) 1998-07-30 2000-02-21 Japan Tobacco Inc. Disubstituted maleimide compounds and medicinal utilization thereof
GB9819035D0 (en) 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
WO2000034242A1 (en) 1998-12-11 2000-06-15 Virginia Commonwealth University Selective 5-ht6 receptor ligands
DE19907701A1 (de) 1999-02-23 2000-08-24 Bayer Ag Mit tricyclischen Indolen substituierte Oxazolidinone
JP4636521B2 (ja) 1999-07-19 2011-02-23 塩野義製薬株式会社 ｓＰＬＡ２阻害作用を有する三環系化合物
ES2290115T3 (es) * 2000-02-01 2008-02-16 ABBOTT GMBH & CO. KG Compuestos heterociclicos y su aplicacion como inhibidores de parp.
FR2805539B1 (fr) * 2000-02-25 2005-06-10 Oreal Compositions de teinture des fibres keratiniques contenant des derives d'indolizine et procede de teinture
ATE258553T1 (de) 2000-03-31 2004-02-15 Ortho Mcneil Pharm Inc Phenyl-substituierte indolizinderivate und deren verwendung als histamin h3 liganden
MXPA03005915A (es) 2000-12-27 2003-09-10 Hoffmann La Roche Derivados de indol y su uso como ligandos receptores de 5-ht2b y 5-ht2c.

Also Published As

Publication number Publication date
EP1807427A2 (en) 2007-07-18
US20060094752A1 (en) 2006-05-04
WO2006050007A3 (en) 2006-08-03
CN101094852A (zh) 2007-12-26
BRPI0517955A (pt) 2008-10-21
JP2008518917A (ja) 2008-06-05
AU2005302559A1 (en) 2006-05-11
CA2585967A1 (en) 2006-05-11
WO2006050007A2 (en) 2006-05-11
US7608626B2 (en) 2009-10-27

Similar Documents

Publication Publication Date Title
MX2007005199A (es) Indolizinas sustituidas y derivados como agentes del sistema nervioso central.
MX2007013021A (es) Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c.
TW200720266A (en) Benzodioxane and benzodioxolan derivatives and uses thereof
TW200718692A (en) Dihydrobenzofuran derivatives and uses thereof
TW200716595A (en) Chromane and chromene derivatives and uses thereof
NO20062139L (no) Dihydrobenzofuranyl-alkanaminderivater som 5HT2C-agonister
TW200719886A (en) Dihydrobenzofuran derivatives and uses thereof
TW200833686A (en) Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
HK1119699A1 (en) Pyridopyrimidinone inhibitors of pi3kalpha
MX2007004699A (es) Derivados de indol y bencimidazol.
MXPA06000716A (es) Derivados de quinolina y quinazolina que tienen afinidad hacia receptores del tipo 5ht1.
GB0504828D0 (en) Therapeutic agents
TNSN05328A1 (en) (thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists
EP1496892A4 (en) 1H-BENZO (F) INDAZOL-5-YL DERIVATIVES AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS
MX2007004794A (es) Tienopiridinas como potenciadores alostericos del receptor muscarinico m4.
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
MX2010001486A (es) Derivados de tetrahidropiridin carboxamida como antagonistas de trpvl.
MX2010002760A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3.
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
WO2008020306A3 (en) Isoindole derivatives
NO20080033L (no) Kinolinderivater som NK3-antagonister
MX2007004661A (es) Derivados de 1-(hetero)aril-3-amino-pirrolidina para usarse como antagonistas del receptor mglur3.
DE602005007765D1 (de) Neue indol- oder benzimidazol-derivate
UA106200C2 (uk) Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину
WO2008052088A8 (en) Chromane derivatives, synthesis thereof, and intermediates thereto